# QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas

> **NCT02582827** · PHASE1 · WITHDRAWN · sponsor: **NantBioScience, Inc.**

## Conditions studied

- Neoplastic Disease

## Interventions

- **DRUG:** ABI-011

## Key facts

- **NCT ID:** NCT02582827
- **Lead sponsor:** NantBioScience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-11-13
- **Primary completion:** 2019-08-23
- **Final completion:** 2019-08-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Enrollment not initiated
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582827, "QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02582827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*